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Introduction
Viruses are a form of life that possess genes but do not have a cellular structure. Viruses do not have their own metabolism, and they require a host cell to make new products; therefore, they cannot naturally reproduce outside a host cell [1] . The complete set of viruses in an organism or habitat is called the virome; for example, all human viruses constitute the human virome [2] . Although there are millions of different types of viruses, only about 5,000 types have been described in detail [3] . A virus has either a DNA or an RNA genome and is called a DNA virus or an RNA virus, respectively.
The objective of this paper is to present the basic practical clinical roles of viruses in patients with hematological diseases including malignancies and non-malignancies, as well as those undergoing hematopoietic cell transplantation (HCT), with the focus on herpesviruses causing latent infections in severely immunocompromised patients.
Classification
The current classification of viruses was developed by The International Baltimore classification of viruses is based on the DNA or RNA of virus and method of mRNA synthesis [4] . Viral genomes may be RNA or DNA, single-stranded (ss) or double-stranded (ds), and may or may not use reverse transcriptase (RT). Additionally, ssRNA viruses may be either sense (+) or antisense (−). The vast majority of viruses have RNA genomes. Baltimore classification divides viruses into seven groups (Tab. I). 
Role of viruses in hematology

Diagnostics of viral infections in hematological patients
Laboratory test for viral infections with focus on latent and chronic infections should be performed in many hematological conditions, especially at diagnosis of the disease, and before HCT (both in recipient and donor). Additionally, after HCT monitoring for CMV and EBV, reactivation is mandatory in allo-HCT setting, and for several other viruses depending on clinical signs and symptoms (Tab. III). Reactivation of latent infections with herpes viruses may lead to various disease manifestations, regardless of its primary acquisition after the transplant. Unlike in the general immunocompetent population, with typical clinical manifestations of infection ranging from asymptomatic to mild or moderate symptoms, HCT recipients may frequently develop much more severe disease.
Viral infections
It is essential to identify patients at risk for reactivation of latent viruses, as active infection and diseases can often be prevented with prophylaxis and preemptive monitoring during the most critical time periods.
Herpes viruses
Herpesviridae create a large family of double-stranded DNA viruses with specific and unique biologic features, enabling them to establish latency program after primary infection in human prior to reactivation later in life. With respect to taxonomy, there are three subfamilies: alpha-, beta-, and gamma-herpes-viridiae, which include nine known human herpesviruses (Tab. IV).
In the most severely immunocompromised patients, which comprise mainly recipients of allo-HCT from unrelated or mismatched donor, four herpesviruses play a major role in chronic latent and relapsing infections including CMV, EBV, HHV6B, and VZV. So far, no pathogenicity was shown for HHV-6A virus. These four viruses are described and discussed in this article. Basic characteristics of these four herpesviruses are shown in table V [5] [6] [7] [8] .
Herpes simplex virus.
HSV-1 and HSV-2 infection is usually associated with mucocutaneous disease in the orofacial region (85%-90%), and rarely in the esophageal and genital area. Rare acyclovir 500 mg/m 2 or 10 mg/kg every 8 h for at least 14-21 days is recommended. HSV resistance occurs in approximately 5%-15% of patients and foscarnet or cidofovir is second-line therapy [5] . 
HHV
Herpes viruses seroprevalence: increasing with age
The human herpesviruses, such as CMV, EBV, HHV6, and VZV, are being the agents of a global infection although differences in the seroprevalence exist between countries: it is the well-documented fact in case of CMV [5] [6] [7] [8] . CMV acquisition in a general population is characterized by an age-dependent rise in seropositivity, which correlates most closely with socioeconomic level as well as race, similarly to other herpesviruses [11] . Seroprevalence of CMV varies from about 40%-50% in highly developed countries to over 90% of population in the developing countries, with the rate from about 30% in childhood to over 50% of women of childbearing age and even up to 60%-70% in adults. However, the incidence slightly decreases with the calendar year. Nevertheless, in population of highly developed countries, CMV acquisition still occurs at a rate of 1%-7% per year [8, 9, [11] [12] [13] .
There is an exception in case of HHV-6, as apart from seroprevalence after acquired infection, mainly in early childhood, there is a congenital phenomenon of chromosomally integrated HHV-6 (CIHHV-6), resulting from vertical transmission: inherited from mother or father.
It occurs both in HHV-6A or HHV-6B with prevalence about 1% in the general population. In case of CIHHV-6, the virus HHV-6 present in every nucleated cell, and HHV-6 DNA can be easily detected in hair follicles and nails. In most cases, there is one copy of HHV-6 DNA/ leukocyte [14, 15] .
Clinical symptoms: many manifestations
Some of herpesviruses have a potential to play a role in pathogenesis of different diseases with various manifestations. This is well observed in case of EBV and CMV, and it happens also for HHV6
and VZV (Tab. VI).
Also CIHHV-6 can be associated with several diseases. There is a good evidence of association with aGVHD and CMV reactivation [14] .
It is probably associated with angina pectoris in general population, and there are known cases of hemophagocytosis with thrombotic microangiopathy in SCID patients, as well as encephalitis post-HCT. The highest risk for EBV reactivation and development of EBV-PTLD is in the case of donor seropositivity, as in majority of cases EBV-PTLD after HCT is of donor origin [7] .
Risk factors and incidence of reactivation
In several studies, the relative frequency of herpes viruses reactivations was analyzed in population of patients after allo-HCT, sometimes also with frequency of other latent viruses. Schmidt-Hieber et al. [17] showed in CNS (patients with encephalitis) incidence of 3% (1% MFD, up to 11% MMUD/haplo) [7] 0.5% (BM/PB) 8.3%-11.6% (CBT) [14, 16] 30%-60% (without prophylaxis) [5] 
MFD (matched family donor); MMUD (mismatched unrelated donor); CBT (cord blood transplantation); BM (bone marrow); PB (peripheral blood)
Wu et al. [18] also analyzed the incidence of viral CNS reactivation of herpesviruses, with overall incidence of 12.4%. The most frequent were as follows: EBV, 57.1%; HSV1, 19.0%; CMV, 14.3%; VZV, 4.8%, and mixed 4.8% (EBV+CMV).
Polish analyses [19] [20] [21] showed the incidence of viral reactivation in children: CMV, 29.2%; EBV, 24.3%; BKV, 22.8%; ADV, 5.2%, and the incidence of HHV6 was 1.5%; however, this virus was not usually being tested in all centers. The respective incidence in adults' patients included the following: CMV, 24.7%; BKV, 5.9%; ADV, 2.9%; EBV, 1.9% [21] .
Diagnostics before HCT: serology
Because of incidence and several strategies of prophylaxis and 
Prophylaxis
With the variety of viruses, there is a variety of evidences on viral prophylaxis (Tab. IX). Only in case of CMV, there is a good quality of evidence to use antivirals. Nevertheless, so far it was not a recommended strategy because of its toxicity of antiviral drugs.
Introduction of letermovir might possibly change this practice, what is
happening already in many centers in other countries [22] .
Passive immunization (specific immunoglobulins) is available for
CMV (CMV-Ig) and VZV (VZ-Ig), whereas it is not available for EBV and HHV6. VZ-Ig is recommended for prophylaxis after exposure (up to 2 years after HCT) in IgG-negative transplant recipients [5] .
CMV-Ig is recommended as an option only for treatment of CMV pneumonia, whereas it is not recommended for prophylaxis or preemptive treatment [22] .
Preemptive approach
Preemptive approach is currently recommended as a posttransplant strategy for CMV and EBV reactivation, whereas it is not recommended for HHV6 and not necessary for VZV infection. This approach is a result of frequency of reactivations and therapeutic in first/second line, and cidofovir CDV in third line of therapy) [22] , and anti-CD20 for EBV (rituximab) [23] . Preemptive therapy (also known as preemptive prophylaxis) should be based on a routine screening for blood DNA-emia by qPCR and administration of drugs in case of positive viremia, usually defined locally by specific cutoff value. It is recommended to start preemptive approach within first 4 weeks after HCT and to continue it at least up to day +100 or longer in case of risk factors for reactivation or presence of graft-versus-host disease and immunosuppressive therapy.
Treatment
The first-line treatment of end-organ disease is based on 
Outcome of infection
Herpes virus infection is always regarded as a serious complications.
The most frequent end-organ diseases have relatively poor outcome, with about 50% survival for CMV pneumonia, 70% for EBV-PTLD, and 50% for HHV6 encephalitis [30] [31] [32] . Only in case of VZV, the outcome is close to 100%; this is because of effective prophylaxis with acyclovir for at least 12 months after HCT. Positive risk factor for good outcome of infection is reduction of immunosuppressive treatment, if possible. On the other hand, another pitfalls of treatment of herpes virus infection are adverse events of antiviral therapy.
Herpes virus infections might have also an impact on transplant outcomes. The results are ambiguous. The summary, based on large studies, is presented in table XI.
Conclusions
Because of high worldwide seroprevalence and latency, infections with herpesviruses are, and will be, frequent. Current strategies of management of CMV and EBV are based on mandatory monitoring of DNA-emia and administration of preemptive therapy if DNA-emia is positive; however, pharmacological prophylaxis is a renewed possibility in case of CMV (letermovir) and is an option for EBV infection (rituximab). In case of HHV-6, no routine screening is 
